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Abstract
Clinical breakpoints are used in clinical microbiology laboratories to categorize microorganisms as clinically susceptible (S), intermediate
(I) or resistant (R) dependent on the quantitative antimicrobial susceptibility as indicated by the MIC value determined in a well-deﬁned
standard test system. The laboratory report, with the designations of S, I or R for each antimicrobial agent, provides guidance to clini-
cians with respect to the potential use of agents in the treatment of patients, and clinical breakpoints should therefore distinguish
between patients that are likely or unlikely to respond to antimicrobial treatment. In Europe, clinical breakpoints are set by the Euro-
pean Committee on Antimicrobial Susceptibility Testing (EUCAST), following a deﬁned procedure. This includes evaluation of efﬁcacy in
experimental settings and clinical studies to derive pharmacodynamic targets such as the fAUC/MIC ratio or %fT > MIC required for
efﬁcacy, the pharmacokinetic properties of the agent, Monte Carlo simulations to estimate exposures of the antimicrobial agent in the
target patient population and commonly used dosing regimens. The probability of target attainment is subsequently determined for a
range of pharmacodynamic targets and the results from the Monte Carlo simulations. The breakpoints derived are subsequently evalu-
ated with respect to the wild-type population of the target microorganisms, speciﬁc resistance mechanisms and other relevant data. In
this paper, we provide an overview of the EUCAST process and considerations for setting pharmacokinetic/pharmacodynamic break-
points. These are the breakpoints that in the EUCAST breakpoint tables are referred to as ‘non-species-related breakpoints’.
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Introduction
Clinical breakpoints are used in clinical microbiology labora-
tories to categorize microorganisms as clinically susceptible
(S), intermediate (I) or resistant (R) dependent on the quan-
titative antimicrobial susceptibility as indicated by the MIC
value determined in a well-deﬁned standard test system. The
laboratory report, with the designations of S, I or R for each
antimicrobial agent, provides guidance to clinicians with
respect to the potential use of agents in the treatment of
patients. The deﬁnition of susceptible by the European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST) is
that ‘A microorganism is deﬁned as susceptible by a level of
antimicrobial activity associated with a high likelihood of
therapeutic success. A microorganism is categorized as sus-
ceptible by applying the appropriate breakpoint in a deﬁned
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phenotypic test system,’ [1–3]. Conversely, resistance is
deﬁned as a high likelihood of therapeutic failure. Ideally, clin-
ical breakpoints should therefore distinguish between
patients that are likely or unlikely to respond to antimicro-
bial treatment. Setting breakpoints involves several factors,
including clinical results from various types of study, wild-
type MIC distributions for relevant species of organisms,
antimicrobial dosing and pharmacokinetic (PK) and pharma-
codynamic (PD) aspects. In this paper, we provide an over-
view of the EUCAST process and considerations for setting
PK/PD breakpoints. These are the breakpoints that in the
EUCAST breakpoint tables are referred to as ‘non-species-
related breakpoints’.
Deﬁning a Pharmacodynamic Target
The key phrase in the EUCAST deﬁnitions of susceptible and
resistant is ‘by a level of antimicrobial activity’. This indicates
that the concentrations, as well as the concentration–time
proﬁle of the antimicrobial agent in the patient, should be
such that an adequate response to therapy can be expected.
In turn, this implies that a certain relationship exists between
the efﬁcacy of an agent and the concentration–time proﬁle
and that a prediction of the likelihood of successful treat-
ment can be made. It has been one of the most important
developments of the last decade that antimicrobial agent
concentration–effect relationships (or rather exposure–
response relationships, as the concentration of the agent that
the infecting organism is exposed to changes over time) have
become apparent. Also, exposures required for particular
responses, such as the probability of successful treatment
outcome, have been established. These ﬁndings were
recently summarized by Ambrose et al. [4], who showed that
exposures required for microbiological and clinical cure in
preclinical models and in humans were in a similar range.
An important consideration is that the efﬁcacy of an anti-
microbial agent is dependent on the relationship between
the MIC for the microorganism and the exposure of the
microorganism to the agent in the patient (or other host).
Clinical outcome is dependent on the triangular relationship
between MIC, exposure and efﬁcacy [5]. In turn, exposure
of the microorganism to the agent in the patient is depen-
dent on the dose and the pharmacokinetic properties of the
drug. For many agents the efﬁcacy of the non-protein bound,
free (f) agent in serum is correlated with the area under the
concentration–time curve (AUC) and inversely correlated
with the MIC (Fig. 1). In other words, the effect is
dependent on the fAUC/MIC ratio. For other antimicrobial
agents this relationship is different. For instance, for b-lactam
agents it is not the fAUC/MIC relationship that best corre-
lates with outcome but the time, expressed as a percentage
of the dosing interval, that the concentration of the antimi-
crobial agent remains above the MIC for the microorganism,
in short the % fT > MIC. These factors correlating with efﬁ-
cacy are called PK/PD indices, because they incorporate
pharmacokinetic (drug concentration over time) and pharma-
codynamic (drug effect over time) factors [6].The underlying
mechanisms that explain these relationships have been
explored by several investigators, and are primarily depen-
dent on the relationship between growth rate and the
dependency of the kill rate on antimicrobial concentrations
[7,8].
The relationship between a PK/PD index and response to
treatment allows for the deﬁnition of a pharmacodynamic
target (PDT). The PDT is the minimum value of the PK/PD
index that is aimed for when treating patients and is based
on preclinical and clinical drug/microorganism exposure–
response relationships. The PDT ideally is the PK/PD index
value that ensures a high probability of successful treatment.
There are two methods that are often used to identify the
PDT. The ﬁrst method is a speciﬁc analysis of the exposure–
response relationship called Classiﬁcation and Regression
Tree analysis and is most often used to analyse exposure–
response relationships in clinical trials [9–17]. This non-para-
metric method involves an algorithm of iterative splitting
(recursive partitioning) and searches for the PK/PD index
value that best discriminates between outcome categories,
FIG. 1. Cure rate after treatment with ﬂuconazole in patients
(n = 132) with oropharyngeal candidiasis. From these patients, the
MIC distribution of the Candida albicans strains causing the infection
was determined. Patients received different doses of ﬂuconazole and
the area under the curve (AUC) was estimated in each patient.
There were seven different fAUC/MIC ratio values, resulting in
seven groups. The proportion of patients cured in each group was
plotted against the AUC/MIC ratio and the relationship was deter-
mined using the Emax model. The ﬁgure clearly shows the propor-
tionality between fAUC and cure rate, whereas the MIC is inversely
proportional to the cure rate [13].
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for instance failures and successes as outcome in clinical tri-
als. The signiﬁcance of classiﬁcation can be tested using vari-
ous statistical analyses such as the Fisher test and validated
using logistic regression analysis. Outcome is usually binomial
(success or failure of treatment), so a signiﬁcant difference
between classes indicates that the PK/PD index that deﬁnes
the classes distinguishes between the class with a high proba-
bility of cure and the class with a low probability of cure.
For example, in a study by Ambrose et al. [9], an fAUC/MIC
ratio of about 34 was found to distinguish between patients
that responded well or poorly to ﬂuoroquinolone treatment
for pneumococcal infection.
The second method commonly used to identify the PDT
examines the full exposure–response relationship and from
this identiﬁes a PDT. If used in clinical trial analysis and a sig-
niﬁcant relationship exists, this is often the exposure that
results in at least 90% cure or the maximum effect. However,
both methods suffer from the fact that in many clinical trials
there are not enough failures to perform such analyses, par-
ticularly for new agents. In clinical trials the dosing regimens
chosen are based on obtaining a high drug exposure and
MICs are usually low, so few patients will have low exposures
and infecting microorganisms with high MICs. The PDT is
therefore most often derived from preclinical studies, such as
studies in animal models [18,19], but in vitro hollow ﬁbre
infection models [20–22] are increasingly used. Most animal
models involve mice that are rendered neutropenic and
infected with an inoculum of 106 CFU/mL of microorganisms
in the thigh or lung. Treatment is then initiated and after 24
or 48 h the total bacterial count is determined for each
organ. Using different doses and dosing intervals, ranges of
exposure are obtained and are subsequently plotted against
the number of CFU to establish exposure–response relation-
ships. In a hollow ﬁbre infection model, bacteria are exposed
to simulated concentration–time proﬁles in an in vitro system.
The advantages over animal models include examination of
the effects of different half-lives and studies at higher inocula
[23]. The latter in particular is used to study the emergence
of resistance. The relationship between exposure and
response (CFU) can generally be described by a sigmoid
curve such as the Emax model with variable slope (Fig. 2).
There are several conclusions that can be derived from this
relationship. It is obvious that increasing values of the PK/PD
index result in an increased effect, and that there is a value
where a near maximum effect is achieved. The three key PK/
PD index values that can be derived from this relationship
are the PK/PD index value that results in a net static effect
(no log10 drop in CFU) over 24 h of treatment (also called
the in vivo static effect) and the values that results in a 1 log10
drop or a 2 log10 drop in CFU. Intuitively, the PK/PD index
resulting in an in vivo static effect is the minimum value
required when treating patients with an intact immune sys-
tem, whereas a higher value may be required in patients that
are immune deﬁcient. Ambrose et al. [4] showed that PK/PD
index values derived from studies in animals and those
obtained by Classiﬁcation and Regression Tree analysis were
very similar; hence, PDTs can be derived from preclinical
studies as well as clinical studies. Although PDTs derived
from preclinical studies and clinical studies may differ for vari-
ous reasons, the differences are generally not large, and both
are taken into account by EUCAST when setting PK/PD
breakpoints. This applies to other PK/PD relationships as
well. For instance, for both quinolones and aminoglycosides
the fAUC/MIC has been shown to be the index best corre-
lated with efﬁcacy, but the peak concentration (Cmax)/MIC
ratio is also considered to be of importance and is taken into
account. However, as most of these drugs are dosed once
daily and are dosed according to a ﬁxed regimen, there is a
strong co-linearity between the various PK/PD indices and so
there are comparable correlations with efﬁcacy.
Deriving Breakpoints from the
Pharmacodynamic Target—the Exposure–
MIC–response Relationship
To attain a particular PDT in each patient, and thereby
achieve a high probability of microbiological and clinical cure,
two conditions need to be met. The ﬁrst is that the expo-
sure of the microorganism to the antimicrobial agent is ade-
quate in each patient. In clinical practice, however, the
exposure is ﬁxed within certain boundaries, because the
doses that are prescribed to patients are standardized, and
are part of the summary of the product characteristics or
FIG. 2. Characteristic effect levels of a sigmoid dose–response
relationship (example for levoﬂoxacin). The plot shows the relation-
ship between area under the curve for free agent (fAUC) and num-
ber of CFU after 24 h of treatment. The static effect line indicates
the fAUC required to result in no net change in CFU after 24 h of
treatment. The 2 log10 drop indicates the fAUC required for a 100-
fold reduction in CFU.
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the hospital formulary. However, the exposure does vary
among patients because of inter-individual variability of phar-
macokinetic parameters such as clearance and volume of dis-
tribution, and these factors should be taken into account
when striving to predict outcome of treatment based on the
PDT. The second condition is that the MIC is low enough to
attain a PK/PD index value above the PDT—the value of the
PK/PD index depending on exposure as well as MIC. Micro-
organisms with MICs that result in PK/PD index values that
are lower than the PDT should be considered resistant (low
probability of cure) whereas those with MICs that result in
PK/PD index values that are higher than the PDT should be
considered susceptible (high probability of cure), and the
clinical MIC breakpoint is then based on the PK/PD index
value that differentiates between the two groups. It is evi-
dent that the value of the breakpoint is directly dependent
on the expected exposure of the microorganism to the anti-
microbial agent in the patient to be treated.
As alluded to above, the expected exposure is dependent
on dose, pharmacokinetic properties and pharmacokinetic
variability in the population of patients to be treated, and
when setting clinical breakpoints each of these should be
taken into consideration. The ﬁrst step therefore is to verify
the dose and dosing regimen that is (or will be) most com-
monly used in the treatment of patients for a certain indica-
tion. This is particularly important for older drugs, where
signiﬁcant differences may exist. For instance, for penicillin,
the most extreme example, the dosing regimens used vary
between 600 mg three times daily to 3 g six times daily [24].
The pharmacokinetic properties of the agent, such as the vol-
ume of distribution and rate of clearance, will then provide
values for PK parameters such as fAUC, and PK/PD indices
are derived by including the MIC. The pharmacokinetic param-
eter is a property of the antimicrobial agent and the patient,
whereas the PK/PD index is also dependent on the MIC.
The simplest method to determine the MIC breakpoint
correlated with a particular exposure or PDT, is to take the
PDT and use the simulated pharmacokinetic curve (based on
pharmacokinetic properties and standard equations) for the
agent directly to calculate the MIC breakpoint value. For
instance, in the previously mentioned study by Ambrose
et al. [9], the PDT derived from Classiﬁcation and Regression
Tree analysis was an fAUC/MIC ratio of 34. The fAUC for a
500-mg dose of levoﬂoxacin is around 40 mg/h/L [25].
Hence, 40 (fAUC)/MIC (breakpoint) = 34 (PDT) and, rear-
ranging the formula, MIC breakpoint = 40/34 = 1 mg/L to
the nearest two-fold MIC value. Similarly, for antimicrobial
agents where efﬁcacy is primarily correlated with the
%fT > MIC, such as b-lactams, the MIC breakpoint can be
derived directly from a PDT such as 40% (static PDT) to
60% (1–2 log drop PDT) fT > MIC. Whereas this method is
straightforward, the disadvantage is that it does not clearly
show the impact of variation in or speciﬁc choice of the
PDT on the MIC breakpoint. This can be achieved by tabu-
lating or plotting the PK/PD index as a function of MIC for
the dosing regimen of interest. For example, in Fig. 3 the
fT > MIC for ceftazidime is shown as a function of MIC for
two different dosing regimens, 1 g three times per day and
500 mg three times per day [10,26]. By drawing a horizontal
line at the PDT on the y-axis, the MIC breakpoint can be
read from the intersection with the plot. This approach
allows direct evaluation of the effect of various PDTs on the
MIC breakpoint. It also facilitates comparison of the effec-
tiveness of different dosing regimens in attaining PDTs [27].
Probability of Target Attainment and
Monte Carlo Simulations
The probable expected exposure in a particular patient is,
however, not only dependent on dose and pharmacokinetic
parameters, but also on the pharmacokinetic characteristics,
which may vary from patient to patient. When a speciﬁc PK/
PD index value is used as a PDT to predict the probability of
successful treatment, this should be true not only for the
population mean, but also for each individual patient within
the population. As the pharmacokinetic behaviour differs for
each individual, the PK part of the PI also differs. Hence,
when designing the dosing regimen that should result in a
FIG. 3. Relationship between fT > MIC and MIC of ceftazidime for
two different dosing regimens of ceftazidime. This illustrates that the
clinical breakpoint is dependent on the dosing regimen. Assuming
that 60% fT > MIC is the pharmacodynamic target (PDT), the break-
point for the dosing regimen of 500 mg three times per day is 4 mg/
L, whereas for the dosing regimen of 1000 mg three times per day
the breakpoint is 8 mg/L. Arrows indicate the PDT and the corre-
sponding breakpoint for the 500-mg dose. Alternatively, a PDT of
40% fT > MIC would result in breakpoints of 8 and 16 mg/L, respec-
tively.
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certain PDT this inter-individual variation should be consid-
ered. As real data deﬁning the variability among individual
patients are rarely available, a statistical approach is taken to
simulate the variation. The statistical method most often
used is Monte Carlo Simulations (MCS). This method was
ﬁrst used by Drusano et al. [28,29] to present an integrated
approach to population pharmacokinetics and microbiological
susceptibility information at the Food and Drug Administra-
tion Anti-infectives Product Advisory Committee. This
method quickly became a standard approach in the process
of setting breakpoints and has been used by EUCAST since
2002. There are several approaches to perform MCS [30].
The most common method involves repeatedly drawing ran-
dom parameter values for each of the pharmacokinetic
parameters, such as volume of distribution and clearance,
based on its population mean and the standard deviation
(SD), and construct simulated curves from those values fol-
lowing standard pharmacokinetic equations. Hence, the vari-
ability of pharmacokinetic parameters is used to simulate
multiple concentration–time curves. A typical simulation
involves 5000–10 000 cycles. As a control and a check that
the random drawing of parameter values represents the ori-
ginal parameter estimate and its SD, the mean and SD of the
simulations are compared with the original values and should
be similar. The same applies to the generated curves, which
can be compared with the original ﬁndings [31]. For each of
the generated pharmacokinetic curves, which are all slightly
different because the input parameters vary to a degree in
relation to the variance of the parameters, the value of the
PK/PD index is determined for a range of MICs. Two differ-
ent methods are used to display the results of MCS. The
ﬁrst approach is to plot or tabulate the probability of target
attainment (PTA) of a PDT as a function of the MIC for a
particular target, or different targets. For example, Table 1
displays the PTA for various PDTs for a 1-g dose of ceftazi-
dime three times daily [10]. The MIC breakpoint follows
from the PDT that is considered necessary and the MIC
range that needs to be covered. For instance, 100% PTA is
attained at an MIC of 4 mg/L using a PDT of 50%
f%T > MIC. Fig. 4 shows results for linezolid, as a plot rather
than a table [32]. Typically, the MIC distribution of the target
microorganisms is displayed in the same ﬁgure. By viewing
the PTA as well as the MIC distribution the relationship
between them is easily perceived. In this case, the PTA sup-
ports a susceptible PK/PD (non-species related) breakpoint
of 2 mg/L and this is also the MIC at the high end of the
wild-type MIC distribution.
As can be observed from Fig. 4, the PTA is close to 100%
at low MICs, and then decreases rapidly to 0 at high MICs.
The slope of the line follows from the distribution of curves
generated by the simulations, and becomes steeper if the
variation in pharmacokinetic parameters is reduced. With a
large variation, the PTA starts to decrease at lower MICs
but decreases more slowly and will approach zero at higher
MICs. The acceptable level of PTA is still under debate. Val-
ues of 99%, 95% or 90% have all been used. However,
whereas 90% is often used it means that 10% of the popula-
tion infected with a microorganism that has the MIC used to
determine the PD index would probably not be covered
optimally, that is, the PDT would not be attained. It should
be noted that it is only the PTA at the MIC breakpoint value
that is considered and not the PTA at lower MICs. The PTA
at lower MICs will be close to 100%, and the accumulative
PTA for the MIC distribution is much higher than for the
breakpoint MIC value alone. In addition, because of the posi-
tion and slope of the line, it could easily be that, for instance,
100% PTA is attained at 1 mg/L, 89% is attained at 2 mg/L
and 70% at 4 mg/L. A breakpoint of 2 mg/L would in that
case be more justiﬁed. In addition, if the PDT was slightly dif-
ferent—the PDT is an estimate in itself—the PTA would be
TABLE 1. Probability of target attainment (%) for various
pharmacodynamic targets for 1 g ceftazidime given three
times daily.
MIC (mg/L)
%fT > MIC
30 40 50 60
0.5 100 100 100 100
1 100 100 100 100
2 100 100 100 100
4 100 100 100 100
8 100 99 84 42
16 54 10 1 0
32 0 0 0 0
From ref. [10]
FIG. 4. Probability of Target Attainment (PTA) of linezolid for three
pharmacodynamic targets (PDTs) 50, 75 and 100, for a range of
MICs. At an MIC of 1 mg/L nearly 100% of the target population is
expected to reach the PDT, whereas at an MIC of 4 mg/L this per-
centage is lower. The wild-type MIC distribution for Staphylococcus
aureus indicated by the bars shows that the full distribution is cov-
ered by the PK/PD breakpoint.
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90% and no discussion would ensue. It is, however, not easy
to determine the effects of these considerations together
from this type of graph. In some cases therefore, a small
range of breakpoint values should be considered, rather than
a single value.
An alternative approach that has also been used is to
present the results of MCS graphically, and was ﬁrst pre-
sented at the CLSI meeting in Tampa in 2004 [33] to dem-
onstrate the EUCAST approach. It has the advantage that it
shows the total probability function irrespective of the tar-
get and therefore provides a more complete picture of the
data [10]. An example is shown in Fig. 5. The fT > MIC for
ceftazidime is displayed as a function of the MIC for a 1-g
dose. The middle line represents the values for the mean of
the population, and is similar to Fig. 3. The lines on both
sides represent the conﬁdence interval (CI) estimations
(percentiles) of the mean values. The MICs that can suppos-
edly be covered with the dosing regimen can be read
directly from the ﬁgure at the intersection of the horizontal
line at the PDT and the lower CI. If a CI of 80% were cho-
sen, this would correspond with the 90% PTA of the
method described above (the upper conﬁdence limit not
being important here). This method of display has the
advantage that the effect of choosing a different PDT can
be observed directly and weighted against all the other evi-
dence for setting a breakpoint. Over the years, EUCAST
has included both the 95% and 99% CI in the plots (in the
plots indicated as percentiles), corresponding to 97.5 and
99.5 PTA, and has used the MIC values that resulted from
these PTAs as the initial value for setting a PK/PD break-
point. The value that ensues usually falls between two two-
fold MIC values. The precision of the PDT estimate, the
width of the conﬁdence interval, the closeness to the lower
or higher MIC, evidence from PK/PD studies, the indication
for use of the drug and the MIC distribution itself are then
taken into consideration before agreeing on the PK/PD
breakpoint. In general, the PK/PD breakpoint based on MCS
is one dilution lower than one that would be generated
from the mean of the population. With agents for which
the AUC/MIC is the PDT, a coefﬁcient of variation (CV) of
the AUC of 30% is common and the 90% CI then corre-
sponds to slightly < 2 CVs, i.e. close to 50% or a one-fold
to two-fold MIC dilution.
Important Considerations
The most important consideration is that while MCS and
PTA are important, they are just two of several tools used
in breakpoint setting. Other relevant information, such as
outcome of clinical trials, use of the drug under speciﬁc cir-
cumstances and clinical experience are also taken into
account by EUCAST and may differ between species. In addi-
tion, data are accumulating that emergence of resistance is
also linked to speciﬁc PK/PD indices and values thereof [34–
36]. Data on emergence of resistance are also increasingly
incorporated in the discussions, but this is not yet systemati-
cally applied because of a lack of data.
One important principle in setting breakpoints is that
clinical breakpoints should, if possible, not divide wild-type
MIC distributions [1,2]. Hence, if PK/PD breakpoints are
derived that do divide the wild-type population, alternatives
are sought. In some cases this has led to an increase in the
breakpoint with notes that a higher dose should be used
(e.g. the levoﬂoxacin breakpoint for Streptococcus pneumo-
niae) and in other cases it is lowered to render all bacteria
intermediate or fully resistant (e.g. the ciproﬂoxacin break-
point for S. pneumoniae) (Fig. 6) and the aztreonam break-
point for Pseudomonas aeruginosa. As a consequence of the
principle of not dividing the WT MIC distribution, a spe-
cies-speciﬁc breakpoint could be higher than the non-spe-
cies (PK/PD) breakpoint and this is usually resolved by
speciﬁc dose recommendations. The identiﬁcation of patient
groups where the agent will be most used and that are
most critical is also an important consideration. For exam-
ple, patients in intensive-care units generally have different
pharmacokinetics with a higher volume of distribution
and lower clearance than most other patients. The use of
different pharmacokinetic parameters in the simulations will
obviously result in different conclusions with respect to the
breakpoints, as was shown in case studies for ceftazidime
FIG. 5 The fT > MIC of ceftazidime displayed as a function of the
MIC for a 1-g dose. The middle line represents the values for the
mean of the population (cf Fig. 3) whereas the lines on both sides
represent the conﬁdence interval estimations (percentiles) of the
mean values obtained by Monte Carlo Simulation. MICs that can sup-
posedly be covered with the dosing regimen can be read directly
from the ﬁgure at the intersection of the horizontal line at the phar-
macodynamic target and the lower conﬁdence interval [10,26].
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[10] and for other agents [37]. MCS was performed using
pharmacokinetic parameters from three different popula-
tions, human volunteers, patients with cystic ﬁbrosis and
patients from the intensive-care unit. In each population the
derived breakpoints were different. EUCAST takes such dif-
ferences into consideration when setting breakpoints, based
on the indication of the drug and its likely use. The clinician
should, however, also be aware of the indications for the
drug and the doses used to set breakpoints. For instance, in
patients with cystic ﬁbrosis, use of a standard dose of ceft-
azidime when P. aeruginosa is reported as susceptible is not
adequate as many of these patients have a higher rate of
clearance and higher doses need to be administered to give
an adequate exposure. In speciﬁc populations, measure-
ments of drug concentrations in the individual patient and
measurements of MICs for infecting organisms may be
worthwhile to ﬁne-tune dosing. This would result in guid-
ance for therapy on an individual basis rather than using a
speciﬁc clinical breakpoint. Finally, it should be realized that
the conclusions based on MCS are primarily based on the
PDT. A higher PDT implies a lower breakpoint, and it is
therefore important to weigh the evidence for the PDT.
The method that EUCAST commonly uses—interpreting
PK/PD index versus MIC plots with conﬁdence inter-
vals—provides the means to do so. Weighting the PDT
applies in particular to new antimicrobial classes and some
old antimicrobial classes. For many existing classes the PDT
will, in general, be known. Unless there is clear evidence
that the PDT for a drug differs from others within the same
class, the PDT will be in the same range and comparable
with others in the class. It should be emphasized, however,
that the PDT is not set in stone and in some cases could
be disputed, in particular when pharmacodynamic data are
scarce. In general, when data are scarce, EUCAST will take
the cautious approach and either not provide a breakpoint
or set a relatively conservative breakpoint.
For susceptibility reports, it should be noted that the ﬁnal
decision on reporting susceptibility is not based on a speciﬁc
breakpoint alone. Expert rules may modify the interpretation
in speciﬁc situations and convert a susceptible or intermedi-
FIG. 6. Probability of Target Attainment (PTA) for levoﬂoxacin (500 mg once per day) (a, left upper panel) and ciproﬂoxacin (500 mg twice per
day) (b, left lower panel), respectively. For levoﬂoxacin, the derived breakpoint is 1 mg/L, based on a pharmacodynamic target of 34. However,
the MIC distribution of the wild-type includes microorganisms with an MIC of 2 mg/L (right upper panel). As the wild-type needs to be fully cov-
ered, the susceptible breakpoint was set at 2 mg/L provided a higher dose was used. For ciproﬂoxacin, the derived pharmacokinetic/pharmacody-
namic (PK/PD) breakpoints were at the lower end of the MIC distribution (right lower panel). The susceptible breakpoint was therefore set at
the lower end of the distribution. Another conclusion could be that the PTA of ciproﬂoxacin is too low to justify its use for pneumococcal infec-
tions.
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ate category to a more resistant one [38]. This normally
implies that there are additional clinical or microbiological
data supporting such modiﬁcations.
In summary, EUCAST has developed tools to use PK/PD
and MCS to set breakpoints by considering the relationship
between PK/PD index and MIC that includes the variability in
both exposure and MIC. The representation of the results of
MCS in graphical or tabular plots of PK/PD index versus MIC
allows an interpretation of this relationship that is otherwise
not readily possible. The breakpoints that are set are primar-
ily based on the pharmacodynamic targets that are available,
the variability (and hence the probability) of target attainment
in the population and the indications and likely use of the anti-
microbial agent. Fig. 7 summarizes this procedure. Finally, EU-
CAST reconsiders PK/PD breakpoints when indications
change signiﬁcantly and/or when dosing regimens change sig-
niﬁcantly.
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